| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 03/26/2009 | US20090081168 Method of forming a peptide-receptor complex with zsig33 |
| 03/26/2009 | US20090081162 Method for downregulating an immune reaction |
| 03/26/2009 | US20090081157 Immunostimulatory Combinations for Vaccine Adjuvants |
| 03/26/2009 | US20090081123 Pharmaceutical compounds |
| 03/26/2009 | CA2700338A1 Anti-aids, anti-tumor, immune system stimulating herbal composition and production method |
| 03/26/2009 | CA2700115A1 Long interspersed nuclear element polypeptide compositions and methods of use thereof |
| 03/26/2009 | CA2699483A1 Compositions and methods for modulating immune function |
| 03/26/2009 | CA2699417A1 S1p receptor modulating compounds and use thereof |
| 03/26/2009 | CA2696298A1 Modulators of cystic fibrosis transmembrane conductance regulator |
| 03/25/2009 | EP2039768A1 Mutant forms of Fas ligand and uses thereof |
| 03/25/2009 | EP2039703A1 Toxin detection method |
| 03/25/2009 | EP2039700A2 Novel anti-inflammatory androstane derivatives |
| 03/25/2009 | EP2039681A1 Cycloalkene derivatives, process for production of the derivatives, and use of the same |
| 03/25/2009 | EP2039368A2 Methods for preventing reactivation of latent virus and controlling virus replication |
| 03/25/2009 | EP2039361A2 Use of immunomodulatory compounds |
| 03/25/2009 | EP2039358A1 Pharmaceutical compositions comprising a macrolide and an acid |
| 03/25/2009 | EP2038306A1 Anti-nkg2a antibodies and uses thereof |
| 03/25/2009 | EP2037966A2 Sialoadhesin-related compositions and methods |
| 03/25/2009 | EP2037961A2 Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity |
| 03/25/2009 | EP2037921A2 Sugar-free storage-stable antihistaminic syrups |
| 03/25/2009 | EP2037906A1 S1p receptor modulators for treating multiple sclerosis |
| 03/25/2009 | EP2037741A1 Compositions and methods relating to novel compounds and targets thereof |
| 03/25/2009 | EP2000469A9 Acylaminopiperidine compound |
| 03/25/2009 | EP1767626B1 Peroral vaccine carrier system |
| 03/25/2009 | EP1592680B9 2-phenylpyran-4-one derivatives as selective cox-2 inhibitors |
| 03/25/2009 | EP1405640B1 Novel immunosuppressants |
| 03/25/2009 | EP1377579B1 Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents |
| 03/25/2009 | EP1299421B1 Antibodies to human mcp-1 |
| 03/25/2009 | EP1287035B1 An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
| 03/25/2009 | EP1050301B1 Medicinal compositions containing 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol |
| 03/25/2009 | CN101394868A Strong immune induction by using combination of adenovirus type-5/type-35 vector and vaccinia virus mva vector |
| 03/25/2009 | CN101394867A Process for preparing water-soluble polyethylene glycol conjugates of macrolide immunosuppressants |
| 03/25/2009 | CN101392252A Lychas mucronatus Kv1.3 blocker gene, preparation method and application |
| 03/25/2009 | CN101392239A Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines |
| 03/25/2009 | CN101392220A Selenium-enriched strong and healthy wine |
| 03/25/2009 | CN101392218A Nutrient health wine brewed by natural honey and Chinese herbal medicine and preparation method thereof |
| 03/25/2009 | CN101392031A Extraction and separation method of inonotus obliquus polysaccharide |
| 03/25/2009 | CN101392012A Partial and full agonists of A1 adenosine receptors |
| 03/25/2009 | CN101391061A Novel antibiotic substitute |
| 03/25/2009 | CN101391000A External medicine composition for treating the eczema and preparation method thereof |
| 03/25/2009 | CN101390925A Composite immunity strengthening agent for fresh water young fish |
| 03/25/2009 | CN101390869A Use of high-purity forsythin in preparing bacteriostasis, antivirus and other medicine |
| 03/25/2009 | CN101390868A Plant polysaccharide and preparation method and use thereof |
| 03/25/2009 | CN101390862A Medicine composition containing mizolastine and preparation method thereof |
| 03/25/2009 | CN101390860A Desloratadine syrup and preparation method thereof |
| 03/25/2009 | CN100471948C Composition of antibody specifically binding to CD20 |
| 03/25/2009 | CN100471873C A series of polypeptide capable of blocking IL-6 |
| 03/25/2009 | CN100471869C Preparation and assaying of peptide dextran possessing detectable oral absorption immune regulation of coriolus versicolor |
| 03/25/2009 | CN100471868C Compositions and methods for WT1 specific immunotherapy |
| 03/25/2009 | CN100471838C VLA-4 inhibitors |
| 03/25/2009 | CN100471495C Fumaric acid-ketotifen dispersion tablet and its prepn process |
| 03/25/2009 | CN100471486C Immunomodulatory compositions, methods of making, and methods of use thereof |
| 03/24/2009 | US7507872 Transgenic toll-like receptor 9 (TLR9) mice |
| 03/24/2009 | US7507839 e,g, 1,5-bis(5-acetyl-4,7-dimethoxybenzofuran-6-yloxy)pentane;potassium channel modulator; antiinflammatory agent, autoimmune diseases; immunosuppressant; multiple sclerosis, rejection of foreign organ transplants |
| 03/24/2009 | US7507807 Expression vector comprising nucleotide sequences coding tumor necrosis factor receptor protein (TWEAK) for use in identifying modulators for treatment of inflammatory, cardiovacullar, vision and cancer disorders |
| 03/24/2009 | US7507795 Zcytor17 ligand cytokine; immunostimulators system, and proliferation and/or development of hematopoietic cells in vitro and in vivo; transcription, gene expression, culturing; anticarcinogenic and antiinflammatory agents; diabetes, pancreatitis, inflammatory bowel disease; autoimmune diseases |
| 03/24/2009 | US7507787 Polynucleotides; induce immunology response; antiinflammatory agents; detection polynucleotide patten |
| 03/24/2009 | US7507767 Sulfonamide-containing benzene derivatives which exhibit anti-inflammatory and immunodulatory activity |
| 03/24/2009 | US7507762 Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 03/24/2009 | US7507712 NOV protein: an anti-angiogenic agent and its use, in particular for the treatment of cancer |
| 03/24/2009 | US7507706 Administering a polypeptide to reduce airway hyper responsiveness or reduce the increase of mucus-containing cells in the airway epithelium; IL-13 binding chains of the interleukin-13 receptor |
| 03/24/2009 | US7507529 genetic amplification of a target nucleic acid in biological samples containing primate T-lymphotropic viruses (PTLVs), include human and simian T-lymphotropic viruses (HTLV and STLV), and detecting the strain of PTLV contained in the sample by determining nucleotide fragments that have been amplified |
| 03/24/2009 | US7507417 Glycoproteins; antigens |
| 03/24/2009 | US7507416 adjuvant compound chosen from the acrylic or methacrylic polymers and the copolymers of maleic anhydride and an alkenyl derivative especially with polyalkenyl ethers of sugars or polyalcohols; heterologus influenza protein |
| 03/24/2009 | US7507414 Therapeutic polypeptide with prolonged shelf-life and increased half life for use in treatment of cell proliferative, cardiovascular, inflammatory and autoimmune disorders |
| 03/24/2009 | US7507407 Immunoliposomes that optimize internationalization into target cells |
| 03/24/2009 | US7507398 Using condensation aerosol (MMAD of less than 5 microns) formed by vaporizing a thin layer of the drug on a solid support and condensing the vapor to treat anxiety, vertigo, alcohol or nicotine withdrawal, sedation, hot flashes, peptic ulcers or for hormone replacement therapy, or pregnancy prevention |
| 03/24/2009 | US7507397 Delivery of muscle relaxants through an inhalation route |
| 03/24/2009 | CA2466877C Compositions useful as ligands for the formyl peptide receptor like 1 receptor and methods of use thereof |
| 03/24/2009 | CA2422380C Pyrazole compounds useful as protein kinase inhibitors |
| 03/24/2009 | CA2407715C Diagnostics and therapeutics for macular degeneration-related disorders |
| 03/24/2009 | CA2377904C Medicament with a protective effect against oxidative-toxic substances, particularly against cardiotoxic substances |
| 03/24/2009 | CA2267456C Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 03/19/2009 | WO2009035068A1 Novel 1,3,3-trimethyl-7-phenyl-3,4-dihydro-1h-quinoxalin- 2-one derivatives |
| 03/19/2009 | WO2009035067A1 Glucocorticoid receptor agonists consisting of 1,3,3-tri- methyl-7-phenyl-3,4-dihydro-1h-quinoxalin-2-one derivatives |
| 03/19/2009 | WO2009034961A1 Method of evaluating human dendritic cells and human cell immunotherapeutic agent |
| 03/19/2009 | WO2009033824A1 Use of a combination of beta-casokinin and cnp-22 as a therapeutic agent |
| 03/19/2009 | WO2009033823A1 Use of a peptide combination comprising urotensin ii as a therapeutic agent |
| 03/19/2009 | WO2009033822A2 Use of a combination of a cathepsin g fragment and teprotide as a therapeutic agent |
| 03/19/2009 | WO2009033820A2 Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis |
| 03/19/2009 | WO2009033819A2 Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids |
| 03/19/2009 | WO2009033818A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033817A2 Use of the combination of the hcv-1 e2 protein (484-499) and the human pancreatic polypeptide as a therapeutic agent |
| 03/19/2009 | WO2009033816A2 Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent |
| 03/19/2009 | WO2009033815A2 Use of the peptide combination ala-pro-gly-pro-arg with cecropin a as a therapeutic agent |
| 03/19/2009 | WO2009033814A2 Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent |
| 03/19/2009 | WO2009033813A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033812A2 Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent |
| 03/19/2009 | WO2009033811A2 Therapeutic uses of muroctasin and kisspeptin13 and compositions thereof |
| 03/19/2009 | WO2009033810A2 Use of antioxidant peptide a (phckrm) and aplha-casein (90-96) as therapeutic agents in eg the treatment of hiv infection |
| 03/19/2009 | WO2009033809A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033808A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033806A2 Use of gly-pro-glu-oh (gpe) as a therapeutic agent |
| 03/19/2009 | WO2009033805A2 Use of somatostatin-14 as a therapeutic agent |
| 03/19/2009 | WO2009033802A2 Antide as a therapeutic agent |
| 03/19/2009 | WO2009033801A2 Syndyphalin alone or in combination with antide as a therapeutic agent |
| 03/19/2009 | WO2009033800A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033799A2 Use of a peptide as a therapeutic agent |
| 03/19/2009 | WO2009033798A1 Combination of motilin and minigastrin as a therapeutic agent |
| 03/19/2009 | WO2009033797A2 Use of apelin-17 and peptide yy as therapeutic agents, eg for treating hbv infection |